Braun Stacey Associates Inc Supernus Pharmaceuticals, Inc. Put Options Transaction History
Braun Stacey Associates Inc
- $2.9 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
256Shares Held
59.3MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$170 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$92.2 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$86.2 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...